Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study

Publisher： Karger

E-ISSN： 1421-9794|58|6|439-444

ISSN： 0009-3157

Source： Chemotherapy, Vol.58, Iss.6, 2013-01, pp. : 439-444

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer

By  

Chemotherapy, Vol. 54, Iss. 3, 2008-06 ,pp. : 228-235

Karger

Access to resources Recommend Favorite

Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer

By  

Chemotherapy, Vol. 59, Iss. 6, 2014-06 ,pp. : 402-406

Karger

Access to resources Recommend Favorite

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

By  

Chemotherapy, Vol. 53, Iss. 1, 2007-01 ,pp. : 44-50

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting

By Darmani Nissar A.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-09 ,pp. : 2930-2955

MDPI

Access to resources Recommend Favorite